Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
| 대상 질환 | Relapsing-remitting Multiple Sclerosis |
|---|---|
| 임상 단계 | 1상 |
| 스폰서 | Cellerys AG |
| 상태 | 완료 |
| 참여자 수 | 11 명 |
| 중재(약물) | CLS12311 low, CLS12311 medium, CLS12311 high, uncoupled RBCs |
| 시작일 | 2024년 6월 18일 |
| 완료일 | 2025년 12월 23일 |
| 결과 공개일 | 2026년 6월 8일 |
요약
RED4MS is a clinical trial to assess the safety and tolerability of autologous peptide coupled red blood cells (CLS12311) in patients with relapsing remitting multiple sclerosis (RRMS). CLS12311 consists of autologous red blood cells (RBCs) coupled with antigenic peptides and aims to treat RRMS by induction of antigen-specific immune tolerance.
Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety of CLS12311]
| CLS12311 Low | 5 events |
|---|---|
| CLS12311 Medium | 28 events |
| CLS12311 High | 16 events |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of — Mapi Pharma Ltd.
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patient — Genzyme, a Sanofi Company
- A Study of Oxidative Pathways in MS Fatigue — University of California, San Francisco
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche
- Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Bioma — Gregory Wu
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche